Abstracts tagged "giant cell arteritis"

Abstract Number: 873 • 2016 ACR/ARHP Annual Meeting
Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Richard Conway¹, Karen Creevey², Michelle Trenkmann³, Geraldine M. McCarthy⁴, Conor Murphy⁵, Douglas J. Veale⁶, Ursula Fearon⁷ and Eamonn S. Molloy⁸, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²St. Vincent's University Hospital, Centre for Athritis and Rheuamtic Diseases, Dublin Academic Medical Centre,, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁴Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁷Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁸Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. The pathogenesis of GCA remains incompletely understood. Current evidence suggests that dendritic…
Abstract Number: 3182 • 2016 ACR/ARHP Annual Meeting
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
Berit Dalsgaard Nielsen¹, Ib Tønder Hansen², Kresten Krarup Keller³, Philip Therkildsen⁴, Ellen-Margrethe Hauge³ and Lars Christian Gormsen⁵, ¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ⁵Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark
Background/Purpose: Fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT is, due to its excellent diagnostic accuracy[1], increasingly used to diagnose large vessel GCA (LV-GCA). However, PET/CT is not always readily…
Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 3183 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Stephan Reichenbach^1,2, Sabine Adler³, Jennifer Cullmann⁴, Harald Bonel⁴, Stefan Kuchen⁵, Felix Wermelinger¹, Diana Dan¹, Michael Seitz¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ⁴Department of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 884 • 2016 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁶ and Peter A. Merkel¹⁷, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁵Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To evaluate health-related quality of life (HRQoL) in a large cohort of patients with giant cell arteritis (GCA) as measured by the 36-item…
Abstract Number: 3197 • 2016 ACR/ARHP Annual Meeting
Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force
Stavros Chrysidis¹, Christina Duftner², Christian Dejaco³, Cristina Ponte⁴, Annamaria Iagnocco⁵, Bhaskar Dasgupta⁶, Maria Antonietta D'Agostino⁷, Eugenio De Miguel⁸, Ulrich Fredberg⁹, Wolfgang Hartung¹⁰, Alojzija Hocevar¹¹, Tanaz A. Kermani¹², Matthew J. Koster¹³, Tove Lorenzen¹⁴, Pierluigi Macchioni¹⁵, Marcin Milchert¹⁶, Naina Rastalsky¹⁷, Chetan Mukhtyar¹⁸, Valentin S. Schaefer¹⁹, Kenneth J. Warrington²⁰, Lene Terslev²¹, George A. W. Bruyn²², Petra Hanova²³, Uffe Møller Døhn²⁴, Esperanza Naredo²⁵, Carlo Alberto Scirè²⁶, Greta Carrara²⁷, Sofia Ramiro²⁸, Andreas P Diamantopoulos²⁹ and Wolfgang A. Schmidt¹⁹, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Medical University Innsbruck, Innsbruck, Austria, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, ⁵Sapienza Università Di Roma,, Roma, Italy, ⁶Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ¹⁰Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Rheumatology, University of California Los Angeles, Santa Monica, CA, ¹³Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ¹⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁵Arcispedale Santa Maria Nuova, Reggio Emilia,, Reggio Emilia, Italy, ¹⁶Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁷St. Elizabeth's Medical Center, Boston, MA, Boston, MA, ¹⁸Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁹Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany, ²⁰Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Rheumatology, MC Groep, Loenga, Netherlands, ²³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁵Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain, ²⁶Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ²⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ²⁸Leiden University Medical Center, Leiden, Netherlands, ²⁹Rheumatology, Haugesund Sanitetsforenings Revmatismesykehus, Haugesund, Norway
Background/Purpose: By a Delphi process, the OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal temporal arteries…
Abstract Number: 894 • 2016 ACR/ARHP Annual Meeting
Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Alexis Jones¹, Joe Li² and Charles Li³, ¹Rheumatology, University College London, LONDON, United Kingdom, ²Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom, ³Royal Surrey County Hospital, Guildford, Great Britain
Background/Purpose: The initial suspicion of Giant cell arteritis (GCA) is often made in the setting of primary care or casualty by a non-rheumatologist. Whilst temporal…
Abstract Number: 897 • 2016 ACR/ARHP Annual Meeting
Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis
Jon Golenbiewski¹ and Alexandra Halalau², ¹Internal Medicine, Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI, ²Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI
Background/Purpose: Previous retrospective studies have suggested that simultaneous bilateral temporal artery biopsy (TAB) may lead to increased detection rates of giant cell arteritis (GCA). The term…
Abstract Number: 898 • 2016 ACR/ARHP Annual Meeting
Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy
Daniel Jo¹, Melissa Fazzari², Donald Brand³, Steven E. Carsons⁴ and Elise Belilos¹, ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Biostatistics, Winthrop University Hospital, Mineola, NY, ³Office of Health Outcomes Research, Winthrop University Hospital, Mineola, NY, ⁴Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY
Background/Purpose: Temporal artery biopsy (TAB) is the gold standard for the diagnosis of Giant Cell Arteritis (GCA), yet is limited by the presence of skip…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 900 • 2016 ACR/ARHP Annual Meeting
The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes
Yannick van Sleen, Qi Wang, Wayel H. Abdulahad, Arjan Diepstra, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Macrophages are critical tissue destructive cells in the immunopathology of patients with giant cell arteritis (GCA). Macrophage precursors, monocytes, can be subclassified in three…
Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Luis Rodriguez Rodriguez¹, Leticia Leon², Inmaculada Morado¹, Zulema Rosales Rosado², Cristina Vadillo Font¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, Benjamín Fernández-Gutiérrez³, Juan A Jover Jover² and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
Abstract Number: 856 • 2016 ACR/ARHP Annual Meeting
Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy
Lindsay Lally¹, Navneet Narula², Nicola Goodfellow³, Raashid Luqmani⁴ and Robert F. Spiera⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pathology, Weill Cornell Medical College, New York, NY, ³Oxford, Oxofrd, United Kingdom, ⁴Oxford, Oxford, United Kingdom, ⁵Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: Aberrant rho-kinase (ROCK) activity is implicated in pathogenesis of several vascular and immunologic disorders. We previously demonstrated evidence of increased ROCK activity in histopathologically…
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
Abstract Number: 1L • 2015 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger², Diana Dan², Peter M. Villiger² and Michael Seitz², ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland
Background/Purpose: Giant cell arteritis (GCA) is characterized by a destructive, granulomatous inflammation in the walls of medium and large-sized arteries. Glucocorticoid (GC) treatment controls symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].